American Heart Journal
Volume 159, Issue 3 , Pages 331-339 , March 2010

Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

  • Renato D. Lopes, MD, PhD

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • John H. Alexander, MD, MHS

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • Sana M. Al-Khatib, MD, MHS

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • ,
  • Jack Ansell, MD

      Affiliations

    • Lenox Hill Hospital, New York, NY
    • ,
  • Raphael Diaz, MD

      Affiliations

    • Estudios Cardiologicos Latinoamerica, Santa Fe, Argentina
    • ,
  • J. Donald Easton, MD

      Affiliations

    • Rhode Island Hospital, Alpert Medical School, Brown University, Providence, RI
    • ,
  • Bernard J. Gersh, MB, ChB, DPhil

      Affiliations

    • Mayo Clinic College of Medicine, Rochester, MN
    • ,
  • Christopher B. Granger, MD

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests: Christopher B. Granger, MD, Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27707.
    • ,
  • Michael Hanna, MD

      Affiliations

    • Bristol-Myers Squibb, Princeton, NJ
    • ,
  • John Horowitz, MD

      Affiliations

    • University of Adelaide, Adelaide, Australia
    • ,
  • Elaine M. Hylek, MD, MPH

      Affiliations

    • Boston University Medical Center, Boston, MA
    • ,
  • John J.V. McMurray, MD

      Affiliations

    • Western Infirmary, Glasgow, United Kingdom
    • ,
  • Freek W.A. Verheugt, MD, PhD

      Affiliations

    • University Medical Center, Nijmegen, The Netherlands
    • ,
  • Lars Wallentin, MD, PhD

      Affiliations

    • Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
    • ,
  • on behalf of the ARISTOTLE Investigators

Received 6 February 2009 ,Accepted 7 July 2009.

References 

  1. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation. 2003;108:711–716
  2. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–125
  3. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–952
  4. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312–318
  5. Lairikyengbam SK, Anderson MH, Davies AG. Present treatment options for atrial fibrillation. Postgrad Med J. 2003;79:67–73
  6. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492–501
  7. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689–2696
  8. Goto S, Bhatt DL, Röther J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855–863
  9. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circulation Cardiovascular Quality and Outcomes. 2008;1:84–91
  10. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690–698
  11. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129:1155–1166
  12. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691–1698
  13. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:546S–592S
  14. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–1106
  15. Cheng TO. Warfarin interaction with herbal drugs and food. Int J Cardiol. 2007;119:107–108
  16. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–e354
  17. Healey JS, Hart RG, Pogue J, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke. 2008;39:1482–1486
  18. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–1912
  19. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–2037
  20. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820–829
  21. Pinto DJ, Orwat MJ, Quan ML, et al. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1, 1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg Med Chem Lett. 2006;16:4141–4147
  22. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007;5:2368–2375
  23. Buller HR. A dose-finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis. In: Presented as a late-breaking clinical trial abstract at: 21st Congress of the International Society on Thrombosis and Haemostasis; July 9, 2007; Geneva, Switzerland. 2007;
  24. Bristol-Myers Squibb and Pfizer provide update on apixaban clinical development program [press release]. Princeton, NJ & New York, NY: Business Wire; August 26, 2008.
  25. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877–2885
  26. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med. 1991;115:256–265
  27. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO Investigators. N Engl J Med. 1993;329:673–682
  28. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart Disease and Stroke Statistics—2010 Update. A Report From the American Heart Association. Circulation. 2009;
  29. DiNisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028–1040
  30. Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments. Curr Med Res Opin. 2006;22:471–481
  31. Fiessinger JN, Huisman MV, Davidson BL, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005;293:681–689
  32. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151
  33. Randomized, Double-Blind Study Comparing Once Daily Oral Rivaroxaban With Adjusted-Dose Oral Warfarin for the Prevention of Stroke in Subjects with Non-Valvular Atrial Fibrillation. ClinicalTrials.gov Identifier: NCT00403767. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00403767?term = nct00403767&rank=1. Last accessed February 4, 2009.
  34. A Phase III Study of Apixaban in Patients With Atrial Fibrillation (AVERROES). ClinicalTrials.gov Identifier: NCT00496769. Clinical Trials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00496769?term=nct00496769&rank=1. Last accessed February 4, 2009.
  35. Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-Dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients with Atrial Fibrillation (BOREALIS-AF). ClinicalTrials.gov Identifier: NCT00580216. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00580216?term=nct00580216&rank=1. Last accessed February 4, 2009.

 RCT reg no. NCT00412984.

PII: S0002-8703(09)00945-4

doi: 10.1016/j.ahj.2009.07.035

American Heart Journal
Volume 159, Issue 3 , Pages 331-339 , March 2010

Article Tools

* Image Usage & Resolution